Indivior Leaps On Phase III Data For Depot Opioid Addiction Treatment

Shares in UK company Indivior jumped by more than 12% on Aug. 17 on the LSE on the back of top-line Phase III data for its monthly buprenorphine depot for opioid addiction, and confirmation that a Q4 2017 US approval is still within its sights.

Indivior PLC is attempting to follow Braeburn Pharmaceuticals SPRL and Titan Pharmaceuticals Inc. down a new avenue for treating opioid addiction by using long-acting formulations of buprenorphine to improve treatment compliance. Braeburn/Titan's Probuphine implant was approved by the US FDA in May after what was a long and difficult path, and Indivior is looking to gaining approval of its product RBP-6000 on the back of new Phase III data by the end of next year.

Indivior's RBP-6000, which is designed to be used together with counselling and psychosocial support, is a "potentially transformational" treatment for...

More from Clinical Trials

More from R&D